| Document |
Document Title |
|
WO/2007/105814A1 |
Disclosed is a novel pest control agent, particularly an insecticide or an acaricide. Specifically disclosed is a substituted isoxazoline compound represented by the general formula (1) below or a salt thereof. Also disclosed is a pest c...
|
|
WO/2007/097403A1 |
It is intended to provide a remedy or a preventive for digestive ulcer being efficacious for ulcer in the small intestine, etc., on which the existing gastric antisecretory agents such as proton pump inhibitors exert no effect, and super...
|
|
WO/2007/096261A2 |
The present invention is concerned with a novel process for the preparation of compounds of formula (I), wherein R1 and R2 are as defined in the description and claims. The compounds of formula (I) are pharmaceutically active substances.
|
|
WO/2007/097279A1 |
Disclosed is a production process using, as an intermediate, a 6-(halomethyl)-1,2-benzisooxazol-3(2H)-one derivative represented by the general formula: Wherein R5 represents a methyl group substituted by at least one phenyl group which ...
|
|
WO/2007/096647A2 |
There is provided a compound of Formula (I): wherein R3, R4, R5, R6, R7, R9, and R10, are independently selected from -H, -OH, hydrocarbyl groups, oxyhydrocarbyl groups, cyano (-CN), nitro (-NO2), and halogens; wherein ring A is optional...
|
|
WO/2007/096576A1 |
Novel compounds of formula (I): wherein R1, R2, R3, R4, m, R5, R6, n and Y are as defined in claim 1; or N-oxides, salts and optical isomers thereof. Furthermore, the present invention relates to processes for preparing compounds of form...
|
|
WO2007073518A9 |
Methods for therapy of cystic fibrosis and other conditions such as cancer are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e., ABC transporters s...
|
|
WO/2007/095602A2 |
The present invention relates to compounds of formula (I), wherein R1 is selected from the group consisting of hydrogen, cycloalkyl, alkyl and haloalkyl; Y is selected from the group consisting of -(CR4aR-4b)m-, -C(O)-, -O-, -N(H)-, -N(a...
|
|
WO/2007/090752A1 |
Compounds of formula I processes for their preparation, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
|
|
WO/2007/092285A2 |
Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease, and Multiple System Atrophy, or other neurodegenerative diseases are provided. The treatment inc...
|
|
WO/2007/092190A2 |
The present invention relates to compounds which modulate the activity of the SlPl receptor, the use of these compounds for treating conditions associated with signaling through the SlPl receptor, and pharmaceutical compositions comprisi...
|
|
WO/2007/087906A1 |
The present invention relates to N-cycloalkyl-benzyl-amide derivatives of formula (I) wherein the substituents are as in the description, their process of preparation, their use as fungicide active agents, particularly in the form of fun...
|
|
WO/2007/086076A2 |
This invention describes a process for the preparation of N-(4-trifluoromethyl)-5-methylisoxazole-4-carboxamide commonly known as leflunomide comprising : (a) reacting ethylaceto acetate, triethylorthoformate, and acetic anhydride with s...
|
|
WO/2007/085451A2 |
The present invention relates to polycyclic compounds of formula (I), processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
|
|
WO/2007/082840A1 |
The present invention relates to compounds of formula (I) wherein R1 to R3 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of disea...
|
|
WO/2007/082910A1 |
Compounds of formula (I), and their pharmaceutically acceptable salts and solvates, wherein X represents -O-, -NH-, -S-, -NHC(=O)- or -NHC(=S)-; R1 represents -H or a hydrocarbon chain; R2 represents -H, alkoxy, amino, a hydrocarbon chai...
|
|
WO/2007/080140A1 |
The present invention relates to compounds of formula (I), wherein s, R1aand R1 to R3 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or preventi...
|
|
WO/2007/080159A2 |
The present invention relates to compounds of formula (I), salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention de...
|
|
WO/2007/079162A1 |
Disclosed are compounds of Formula (1), including all geometric and stereoisomers, N-oxides, and salts thereof, Formula (1) : wherein A1, A2, A3, A4, A5 and A6 are independently, selected from the group consisting of CR3 and N; provided ...
|
|
WO/2007/072164A2 |
The present application is directed to a new class of isoxazoles and their use as estrogen modulators.
|
|
WO/2007/071900A1 |
Compounds of formula I: wherein R1, R2, R3, R4, m, R5, R6, n and Y are as defined in claim 1; or N-oxides, salts and optical isomers thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I),...
|
|
WO/2007/071311A1 |
2-Phenylethylamino substituted carboxamide derivatives of formula (I); wherein J, W, R, R0 R1, R2, R3, and R4 have the meanings as defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions co...
|
|
WO/2007/069773A1 |
The present invention provides a novel modulator of the TRPV1-receptor function, comprising a compound of the formula; wherein ring A is an optionally substituted carbocycle or heterocycle, ring B is an optionally substituted benzene rin...
|
|
WO/2007/068330A1 |
The present invention relates to 2-adamantylurea derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of m...
|
|
WO/2007/067817A1 |
The present invention provides compounds having the structure of Formula (I), wherein R1 is optionally substituted lower alkyl, optionally substituted cycloaikyl, or optionally substituted aryl; R2 is hydrogen, carboxyalkyl, optionally s...
|
|
WO/2007/067710A1 |
Provided are chemical entities chosen from compounds of Formula (I) and pharmaceutically or cosmetically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof. The chemical entities modulate TRPV1 a...
|
|
WO/2007/063950A1 |
A compound represented by the formula (I) or a salt or solvate of the compound; a composition and a kit containing any of these which are for use in the diagnosis of conformation diseases; a medicinal composition containing any of these ...
|
|
WO/2007/060026A1 |
The present invention provides compounds of formula (I): in which Y is oxygen or sulphur; R1 and R”1 are optionally substituted aryl, heteroaryl or a fused ring structure, R2 and R'2 are each H, or optionally substituted alkyl, alkylam...
|
|
WO/2007/055928A1 |
E-metanicotine-type compounds that include a five-membered heteroaryl ring linked to an olefinic linker, such as a 4-penten-2-yl linker, which is linked to a terminal amine group, are disclosed. Patients susceptible to or suffering from ...
|
|
WO/2007/056469A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
|
WO/2007/052843A1 |
Disclosed is a FXR inhibitor comprising a compound represented by the formula (I') or a salt or a prodrug of the compound or salt: wherein each symbol is as defined in the description. The FXR inhibitor has an excellent FXR-inhibiting ef...
|
|
WO/2007/051847A1 |
Compounds of Formula (I): (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.
|
|
WO/2007/053436A1 |
The invention provides novel non-peptidic NPY Y2 receptor inhibitors (1) useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a...
|
|
WO/2007/048557A1 |
Compounds of the formula (I), wherein R1, R2, X and N are as defined in the specification; L is F, NH2, NHAlk or N(Alk)2 n is 1 or 2; A' and A" are terminal groups as defined in the specification. The compounds have utility as HIV-1 prot...
|
|
WO/2007/046411A1 |
3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-[[amino(morpholin-
4-yl)methylene]amino]isoxazole is an isoxazole compound useful as a therapeutic agent for an autoimmune disease. The isoxazole compound can be stabilized by using an antioxidan...
|
|
WO/2007/047305A1 |
The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal depositi...
|
|
WO/2007/041969A1 |
The present application belongs to pharmaceutical field of inflammation, immunity and infection. The present application has disclosed glycyrrhetinic acid-30-acidamide derivatives and their preparation methods, as well as pharmaceutical ...
|
|
WO/2007/043457A1 |
It is intended to provide a remedy or a preventive for hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy, diabetic retinitis and so on which has a non-nucleic acid structure and exerts an excellent xanthine oxidase in...
|
|
WO/2007/037187A1 |
A sulfonamide derivative having DP receptor antagonistic activity; and a medicinal composition and a therapeutic agent for allergic diseases which each contains the compound as an active ingredient. The derivative is a compound represent...
|
|
WO/2007/034035A1 |
The invention relates to sulphonamide derivatives of formula (I), where Rc is selected from a group consisting of dialkylamino, NO2, CN, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkanoyl, oxazol-2-yl, oxazolylaminocar...
|
|
WO/2007/032441A1 |
Disclosed is a method for efficiently producing 1,2-benzisoxazole-3-methanesulfonic acid wherein 1,2-benzisoxazole-3-acetic acid in toluene is reacted with chlorosulfonic acid, which may optionally be mixed with an inert solvent, in the ...
|
|
WO/2007/033002A1 |
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: (F) where the definitions of the variables Q, L1, , L2, M, X, L3, and A are provided ...
|
|
WO/2007/030582A2 |
A compound of formula I wherein R1, R2, R3, R4 and R5 are described herein.
|
|
WO/2007/027230A2 |
The present invention relates to prodrugs and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and...
|
|
WO/2007/026965A1 |
Disclosed is a novel harmful organism-controlling agent, particularly an insecticide or acaricide. An isoxazoline-substituted benzamide compound represented by the general formula (1) or a salt thereof; and a harmful organisms-controllin...
|
|
WO2006138510B1 |
The present invention is related substituted enaminones represented by a compound of Formula I that are novel allosteric modulators of a7 nAChRs. The invention also discloses the treatment of disorders that are responsive to enhancement ...
|
|
WO/2007/025247A2 |
Transglutaminase inhibitors and methods of use thereof are provided.
|
|
WO/2007/024836A2 |
The present disclosure relates to the preparation and use of tetrahydro-1,8-dioxa-4a-aza-naphthalenes in low VOC coatings.
|
|
WO/2007/025303A2 |
The invention provides non-steroidal ligands for the androgen receptor, methods for making non-steroidal ligands of the androgen receptor, compositions of non-steroidal ligands of the androgen receptor and methods of using non-steroidal ...
|
|
WO/2007/022529A2 |
Disclosed are methods of treating inflammatory diseases and disorders, such as arthritis and inflammatory bowel disease, in mammals.
|
